

Original Paper

Changes in Intrapersonal Factors of Participants in the Pregnancy Remote Monitoring Study Who Are at Risk for Pregnancy-Induced Hypertension: Descriptive Quantitative Study

Dorien Lanssens^{1,2,3*}, MSc, PhD; Thijs Vandenberk^{1*}, MSc, PhD; Valerie Storms¹, MSc, PhD; Inge Thijs¹, MSc, PhD; Lars Grieten¹, MSc, PhD; Lotte Bamelis⁴, MSc, PhD; Wilfried Gyselaers^{1,2,3}, Prof Dr, PhD; Eileen Tang⁵, PhD; Patrick Luyten^{5,6,7}, PhD

¹Limburg Clinical Research Center/Mobile Health Unit, Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium

²Department of Obstetrics and Gynaecology, Ziekenhuis Oost-Limburg, Genk, Belgium

³Faculty Medicine and Life Sciences, Department of Physiology, Hasselt University, Diepenbeek, Belgium

⁴Centre for Translational Psychological Research TRACE, Ziekenhuis Oost Limburg, Genk, Belgium

⁵Faculty of Psychology and Educational Sciences, KULeuven, Leuven, Belgium

⁶Faculty of Psychology and Educational Sciences, Vrije Universiteit Brussel, Brussel, Belgium

⁷Educational and Health Psychology, Research Department of Clinical, University College London, London, United Kingdom

*these authors contributed equally

Corresponding Author:

Dorien Lanssens, MSc, PhD

Limburg Clinical Research Center/Mobile Health Unit

Faculty of Medicine and Life Sciences

Hasselt University

Martelarenlaan 42

Hasselt, 3500

Belgium

Phone: 32 494919476

Email: dorien.lanssens@uhasselt.be

Abstract

Background: The peripartum period, defined as the period from the beginning of the gestation until 1 year after the delivery, has long been shown to be potentially associated with increased levels of stress and anxiety with regard to one's transition to the status of parent and the accompanying parental tasks. Yet, no research to date has investigated changes in intrapersonal factors during the peripartum period in women at risk for pregnancy-induced hypertension (PIH).

Objective: The aim of this study is to explore and describe changes in intrapersonal factors in participants at risk for PIH.

Methods: We used an explorative design in which 3 questionnaires were sent by email to 110 participants the day following enrollment in the Pregnancy Remote Monitoring program for pregnant women at risk for PIH. Women were invited to complete the questionnaires at the beginning of their participation in the Pregnancy Remote Monitoring project (mostly at 14 weeks of gestation) and after approaching 32 weeks of gestational age (GA). The Generalized Anxiety Disorder-7 Scale (GAD-7) and the Patient Health Questionnaire-9 were used to assess anxiety and depression, and adaptation of the Pain Catastrophizing Scale was used to measure trait pain catastrophizing.

Results: Scores were significantly higher at 32 weeks of GA than at the moment of enrollment (GAD-7 score=7, range 4-11 vs 5, range 3-8; $P=.01$; and Patient Health Questionnaire-9 score=6, range 4-10 vs 4, range 2-7; $P<.001$). The subscale scores of the Pain Catastrophizing Scale were all lower at 32 weeks of GA compared with 14 weeks of GA (rumination: 4, range 1-6 vs 5, range 2-9.5; $P=.11$; magnification: 3, range 1-5.5 vs 4, range 3-7; $P=.04$; and helplessness: 5, range 2-9 vs 6, range 3.5-12; $P=.06$). The proportion of women with a risk for depression (GAD-7 score >10) was 13.3% (10/75) at enrollment and had increased to 35.6% (26/75) at 32 weeks of GA.

Conclusions: This study shows that pregnant women at risk for PIH have higher levels of stress and anxiety at 32 weeks of GA than at the moment of enrollment. Further research is recommended to investigate potential strategies to help pregnant women at risk for PIH manage feelings of stress and anxiety.

Trial Registration: ClinicalTrials.gov NCT03246737; <https://clinicaltrials.gov/study/NCT03246737>

(*J Med Internet Res* 2023;25:e42686) doi: [10.2196/42686](https://doi.org/10.2196/42686)

KEYWORDS

intrapersonal factors; peripartum period; pregnancy; pregnancy-induced hypertension; remote monitoring

Introduction

The peripartum period, defined as the period from the beginning of gestation until 1 year after delivery, has long been shown to be potentially associated with increased levels of stress and anxiety with regard to one's transition to the status of parent and the accompanying parental tasks [1]. It is normal for expectant or new mothers to report anxiety and stress symptoms. Up to two-thirds of women experience worries, most commonly consisting of fear about having an abnormal baby; complications during pregnancy or birth; their ability to care for the baby, including breastfeeding and soothing the infant when crying; as well as concerns about body changes, partner relationships, job performance, finances, cleanliness, etc [2]. Elevated untreated perinatal anxiety may negatively impact maternal health [3-5]; the child's cognitive [6], emotional, and behavioral development [7]; and the mother-infant relationship [8]. Given this, the detection of problematic anxiety through the use of an effective screening tool may be important in screening for risk of problematic anxiety, prevention, early intervention, and treatment in the field of perinatal mental health [9]. Despite the fact that heightened maternal preoccupation in the perinatal period proved to have an adaptive function, particular physical and somatic at-risk circumstances of pregnancy may potentially fuel already increased levels of stress and anxiety to the extent of becoming maladaptive or psychopathological [10,11].

A medically high-risk pregnancy is defined as "any pregnancy in which there is evidence of an actual or potential threat of harm to the life or health of the mother or the baby because of a disorder or situation coincidental with or unique to pregnancy" [12]. Health conditions that lead to increased risk can be obstetrical (eg, placenta previa), maternal (eg, preeclampsia), or fetal (eg, prematurity) [13]. These complications affect approximately 15%-20% of pregnancies annually [14,15]. Medical complications impact not only the health and well-being of the mother but also her developing infant (and the entire family) [16]. Aside from the physical implications, a medically complicated pregnancy can also be a source of significant stress and anxiety for mothers [3,17,18]. Medical complications of pregnancy can invoke stressful emotional pre- and postpartum responses in parents which differ from the usual stress associated with parenthood [19]. In particular, medical complications give rise to feelings of lack of control, worry about the fetus, and uncertainty regarding pregnancy outcomes, which add to women's distress and anxiety levels [20]. A recent study has shown that women experiencing a medically high-risk pregnancy have a 5.17-times higher incidence of anxiety disorders compared to women experiencing a medically low-risk pregnancy [21,22]. The extant literature indicates that anxiety among women experiencing a medically complicated pregnancy is an important area of investigation [16].

Pregnancy-induced hypertension (PIH) complicates between 6% and 10% of all pregnancies and can turn a low-risk pregnancy into a high-risk pregnancy. It is defined as an in-office measurement with a systolic blood pressure (BP) above 140 mm Hg and a diastolic BP above 90 mm Hg. Severe range BP is above 160 mm Hg systolic and 110 mm Hg diastolic. PIH refers to one of four conditions: (1) preexisting hypertension, (2) gestational hypertension, (3) preeclampsia, and (4) unclassified hypertension. PIH is one of the leading causes of maternal morbidity and mortality. Hypertensive disorders may result in fetal complications such as growth restriction, oligohydramnios, placental abruption, preterm birth, and perinatal death [23,24]. The usual care for women with pregnancies complicated by PIH comprises clinical follow-up, serological investigation, and fetal ultrasound evaluation. The type and frequency of follow-up depends on the nature and severity of the hypertensive disorder [23]. The goal of treatment is to prevent significant cerebrovascular and cardiovascular events in the mother without compromising fetal well-being [25]. As explained before, the peripartum period has long been known to be associated with increased levels of stress and anxiety related to the transition to parenthood and parental tasks and concerns associated with this transition [1]. However, when PIH is present, it potentially increases the already elevated levels of stress and anxiety associated with this normative and normally adaptive heightened "maternal preoccupation" in the perinatal period [10,11]. In this context, cognitive factors, such as catastrophizing or rumination, insecure attachment styles, and personality factors, such as perfectionism and dependency, have been associated with problems in negotiating the challenges of parenthood, which are expressed as increased levels of anxiety and depression [26-28].

New techniques to support these strategies have recently been developed, including remote monitoring (RM), which can broadly be defined as the use of telecommunication technologies to facilitate the transmission of medical information and services between health care providers and participants [29]. RM is a relatively new approach that facilitates patient management at home [30]. As part of the Limburg Clinical Research Center in collaboration with Hasselt University, Ziekenhuis Oost-Limburg (Genk), a large hospital in the east of Belgium, added RM to the usual prenatal care of women with PIH. This project is called the Pregnancy Remote Monitoring (PREMOM) project. A previous publication explored the role of participants' psychosocial characteristics (severity of depression or anxiety, cognitive factors, attachment styles, and personality traits) in their adherence to RM. The study demonstrated the relationships between adherence to RM and patient characteristics in women at risk of PIH. Alertness toward the group of women who show less than optimal adherence is essential. These findings call for further research on the management of PIH and the importance of individual tailoring of RM in this patient group [31]. In the

ongoing PREMOM II study (a multicentric randomized controlled trial [32]) is this rationale included for further investigation on a larger sample size. The first results are expected in 2024.


In developing those new strategies (including RM) to optimize the obstetric care of pregnant women at risk for PIH, it is important to investigate patient characteristics and intrapersonal factors. To the best of our knowledge, no research to date has been conducted about changes in the intrapersonal factors during the peripartum period in women at risk for PIH. Therefore, the primary aim of this study was to explore potential changes in anxiety and depression during pregnancy, from the moment of enrollment in the PREMOM I study (at, on average, 14 weeks of gestational age [GA]) to 32 weeks of GA. Our hypothesis was that anxiety and depression would have increased by 32 weeks of GA compared to the moment of enrollment due to the fact that delivery and associated complications are imminent. The secondary aim of this study was to study the level of catastrophizing at both measurement moments. We hypothesized that the levels of catastrophizing would increase between the inclusion enrollment and 32 weeks of GA due to pregnancy-related symptoms.

Methods

The PREMOM I study

The PREMOM I study was set up in January 2015 as a collaboration in Belgium between Hasselt University, Ziekenhuis Oost-Limburg (Genk), and 7 other hospitals (AZ Vesalius, Tongeren; Heilig Hart Ziekenhuis, Mol; JESSA, Hasselt; Maria Ziekenhuis Noord Limburg, Overpelt; Sint Franciskusziekenhuis, Heusden; S. Trudo, Sint Truiden; and Ziekenhuis Maas & Kempen, Maasmechelen). Women who participated in the PREMOM I study received obstetric surveillance through a BP monitor, an activity tracker, and a weight scale. They were asked to perform 2 BP measurements each day (morning and evening), to wear the activity tracker continuously, and to register their weight once a week in the app. This information was to be recorded until the moment of their delivery or until they were admitted to the hospital. The data collected using these devices were transferred to a web-based dashboard developed by the Mobile Health Unit (Limburg Clinical Research Center, Hasselt University; Ziekenhuis Oost-Limburg; Jessa). Predefined alarm signals were developed. Alarm signals were communicated to the responsible obstetrician so that treatment options could be agreed upon with the midwife before the pregnant woman was contacted. The therapeutic interventions were in line with local treatment procedures. The workflow is summarized in Figure 1.

Figure 1. Workflow of the PREMOM I study. PREMOM: Pregnancy Remote Monitoring.



In the past few years, our research team has published several articles related to the PREMOM I study that demonstrated the benefit of RM for pregnant women at elevated risk of developing PIH. Two articles made comparisons between women who received RM and women who had an increased risk of developing PIH but did not participate in the PREMOM I study (conventional care group and control group [CG]) based on a retrospective and observational design. In both studies, prenatal hospitalization to a prenatal ward (until the moment of delivery), diagnosis of preeclampsia, and number of inductions were reduced in the RM group compared with the CG. However, women in the RM group had significantly higher risks of

developing gestational hypertension and a spontaneous start of the birth process compared with the CG. In the study conducted in 2015, the total number of neonatal hospitalizations in the neonatal intensive care unit was lower in the RM group than in the CG group; these findings were not confirmed in the study conducted in 2015-2016. In the later study, the total number of prenatal visits was lower in the RM group than in the CG group; this difference was not apparent in the earlier study [33-35].


Participants

The process of patient enrollment is shown in Figure 2. A total of 124 pregnant women from the PREMOM study were invited

to participate in this study. Seven (5.65%) of them refused to participate because of a lack of interest. Of the remaining 117 pregnant women, 7 (5.65%) were hospitalized at the prenatal ward due to complications before they could fill out the questionnaires. In total, 110 pregnant women (response rate:

88.71%) completed the questionnaires at the start of their participation in the PREMOM project. At 32 weeks of GA, 75 of them (retention rate: 68.18%) also filled out the questionnaires.

Figure 2. Patient enrollment.



Data Collection

For this study, an explorative and descriptive quantitative design was used. Pregnant women were given written information about the study when they received their BP monitor and activity tracker at the start of their RM program. The following day, all participants received an email containing a SurveyMonkey link. After logging in, the participants were asked to complete 3 questionnaires (see subsection Questionnaires) at 2 moments in time: the day following their enrollment in the RM program and at 32 weeks of GA. Demographic and obstetric characteristics of the participants were collected at the moment of enrollment in the PREMOM program and after delivery, through the hospital administration or billing records.

Questionnaires

The Generalized Anxiety Disorder-7 scale (GAD-7) was used to detect anxiety disorders. The GAD-7 was developed within the classical theory as a brief, dimensional screening instrument that aims at identifying probable cases of anxiety disorder and also assessing symptom severity [36]. Simpson et al [37] stated that the GAD-7 represents a clinically meaningful instrument

for screening in a perinatal population. The GAD-7 consists of 7 items to be rated on a balanced 4-point Likert scale ranging from 0 (“not at all”) to 3 (“almost every day”). In addition, the Patient Health Questionnaire-9 (PHQ-9) [38] was used to measure the severity of depression. The PHQ-9 was developed for use in primary care settings and has been extensively tested for validity among diverse populations [39]. Nine questions were asked to be scored on a 4-point Likert scale ranging from 0 (not at all) to 3 (almost every day). Finally, the Pain Catastrophizing Scale (PCS) is used to assess the severity of worry in the context of actual or anticipated pain. It conceptualizes catastrophizing as a multifaceted construct with 3 dimensions, each with a separately summed score: rumination (“I can’t stop thinking about how much it hurts”), magnification (“I worry that something serious may happen”), and helplessness (“There is nothing I can do to reduce the intensity of the pain”). The PCS consists of 13 items, which query the 3 subscales to be rated on a balanced 5-point Likert scale ranging from 1 (“not applicable at all”) to 5 (“fully applicable”) [40]. The scores are calculated for each subscale, and the total scores are used. This questionnaire has been adapted by the research team to refer to

pregnancy-related questions. For all 3 questionnaires, higher scores indicate higher levels of feelings of depression, anxiety, and catastrophizing, respectively.

Statistical Analysis

Data analysis was performed using R statistical software (version 3.2.2; R Foundation). No data imputation was performed for missing data. The study sample size was based on an a priori sample size calculation with a power of minimum 70 participants. The Shapiro-Wilk test was used to assess whether or not the data were normally distributed. Nonparametric tests were used in case where the normality assumption was violated. Skewed data are expressed as a median and IQR. Independent *t* tests (parametric) or Mann-Whitney *U* tests (nonparametric) were used for between-group comparisons. Both dimensional and categorical analyses were performed. For the PCS, catastrophizing was dichotomized as described by Olsson et al [41]. The 2 categories are labeled as “noncatastrophizing” (≤ 17 for the total sum) and

“catastrophizing” (> 17 for the total sum). A score of more than 38 is classified as “clinically relevant.” *P* values $< .05$ were considered statistically significant.

Ethical Considerations

The study was approved by the Ethical Committee of the Ziekenhuis Oost-Limburg (15/093U - B371201526777) and all participants provided written informed consent. The study was also registered at ClinicalTrials.gov (NCT03246737).

Results

Participants Demographics

In total, 75 participants completed all questionnaires at both time points. Patient mean age was 30 (28.0-32.5) years, and 28 (37.3%) of the women were pregnant for the first time. Table 1 provides detailed information about the demographics of the study participants.

Table 1. Demographics of the study participants (N=75).

	Participants
Age (years), mean (SD)	30 (28-32.50)
Prepregnancy weight (kg), mean (SD)	79.97 (18.78)
Height (cm), mean (SD)	166.9 (7.1)
BMI (kg/m ²), mean (SD)	27.68 (23.84-31.87)
Primigravida, n (%)	28 (37.33)

The Evolution of Anxiety, Depression, and Level of Catastrophizing During Pregnancy

The results (Table 2) showed that the levels of anxiety, depression, and several aspects of catastrophizing changed statistically over time. Pregnant women at 32 weeks of GA feel more anxiety and depression than women at the moment of

enrollment (GAD-7 score=7, range 4-11 at 32 weeks of GA vs 5, range 3-8; $P=.01$ at the moment of enrollment; and PHQ-9 score=6, range 4-11 at 32 weeks of GA; and 4, range 2-7; $P<.001$ at the moment of enrollment). Only magnification was significantly lower at 32 weeks of GA compared to the moment of enrollment (3, range 1-5.5 at 32 weeks vs 4, range 3-7; $P=.04$ at the moment of enrollment).

Table 2. Overview of study results.

	Enrollment (N=75), median (IQR)	32 weeks (N=75), median (IQR)	<i>P</i> value
Anxiety and depression			
GAD-7 ^a	5 (3-8)	7 (4-11)	.01 ^b
PHQ-9 ^c	4 (2-7)	6 (4-10)	<.001 ^d
Catastrophizing-PCS^e scale			
Rumination	5 (2-9.5)	4 (1-6)	.11
Magnification	4 (3-7)	3 (1-5.5)	.04 ^b
Helplessness	6 (3.5-12)	5 (2-9)	.06

^aGAD-7: Generalized Anxiety Disorder scale.

^b $P<.05$.

^cPHQ-9: Patient Health Questionnaire.

^d $P<.001$.

^ePCS: Pain Catastrophizing Scale.

In [Table 3](#) the number of participants in each anxiety and depression category is shown. Based on the GAD-7, 10 (13.33%) pregnant women of the 75 were clinically anxious (score \geq 10) at the time of enrollment and 26 (34.67%) of the 75

at 32 weeks of GA. On the PHQ-9 questionnaire, 7 (9.33%) of the 75 pregnant women were clinically depressed (score \geq 10) at the time of enrollment and 22 (29.33%) of the 75 at 32 weeks of GA.

Table 3. Overview of participants in questionnaire category.

	Enrollment (N=75), n (%)	32 weeks GA ^a (N=75), n (%)
GAD-7^b		
0-4	37 (49.33)	22 (29.33)
5-9	28 (37.33)	27 (36)
10-14	5 (6.67)	20 (26.67)
15-21	5 (6.67)	6 (8)
Clinically not anxious (score <10)	65 (86.67)	49 (65.33)
Clinically anxious (score \geq 10)	10 (13.33)	26 (34.67)
PHQ-9^c		
0-4	44 (58.67)	27 (36)
5-9	24 (32)	26 (34.67)
10-14	4 (5.33)	18 (24)
15-21	3 (4)	45 (33)
Clinically not anxious (score <10)	68 (90.67)	53 (70.67)
Clinically anxious (score \geq 10)	7 (9.33)	22 (29.33)

^aGA: gestational age.

^bGAD-7: Generalized Anxiety Disorder-7 scale.

^cPHQ-9: Patient Health Questionnaire-9.

Based on the PCS, 25 (33.33%) pregnant women of the 75 crossed the cutoff value of more than 17 for the total sum described by Olsson et al [41] at the time of enrollment. Three (4%) of the 75 pregnant women scored more than 38 and are

classified as clinically relevant. At 32 weeks of GA, 25 (33.33%) of the 75 pregnant women scored more than 17, while 4 (5.33%) of the 75 pregnant women had a higher score than 38 ([Table 4](#)).

Table 4. Overview of catastrophizing on the Pain Catastrophizing Scale (PCS; N=75).

	Noncatastrophizing (\leq 17), n (%)	Catastrophizing (>17), n (%)	Clinically relevant (>38), n (%)
Enrollment	50 (66.67)	25 (33.33)	3 (4)
32 weeks GA ^a	50 (66.67)	24 (32)	4 (5.33)

^aGA: gestational age.

Discussion

We sought to explore and describe potential changes in some intrapersonal factors of participants at risk for PIH. To the best of our knowledge, this is the first publication targeting this change in psychological factors during pregnancies at risk of this complication. Two interesting sets of findings emerged.

Principal Results

First, in line with our expectations, scores on the GAD-7 and PHQ-9 were higher at 32 weeks of GA compared to the moment of enrollment. The scores on the subscales of the PCS were all lower at 32 weeks of GA compared with 14 weeks of GA. Regarding the primary end point (higher score for anxiety and

depression at 32 weeks compared to 14 weeks), this hypothesis can be adapted. This study showed that pregnant women with PIH followed a normal pattern of increased pregnancy scores, as described by Biaggi et al [42]. The proportion of pregnant women identified by the GAD-7 with a risk for anxiety (GAD-7 score >10) was 13.3% (10/75) at enrollment and had risen to 35.6% (26/75) during 32 weeks of GA. This is higher than the reported 8.5% of pregnant women surveyed in the GAD-7 by Sutter-Dalay et al [28] and the 9.9% prevalence described by Melville et al [43]. Additionally, the scores on the PCS for pregnant women at risk of PIH are in line with those of women experiencing a normal pregnancy; for both women with and without a risk for the development of PIH, the risk for anxiety and depression is low at the onset of the pregnancy compared to the end of the pregnancy [44].

Regarding the second research aim of this study, catastrophizing in women included in this study decreased significantly for the subscale “magnification,” but was relatively stable for the subscales “rumination” and “helplessness,” and for the categorical approach. This is in line with the reported stability of catastrophizing over time during a normative pregnancy [40]. However, the study of Ollson et al [41] reported that levels of catastrophizing changed (both increased and decreased) over time in a minority of participants. So, instead of the stable PCS score for the subscale “magnification” for normal pregnancy, pregnant women with a PIH have a significantly reduced score on this subscale.

Pregnancies Complicated With PIH Compared to Low-Risk Pregnancies

GAD-7

For the GAD-7, Zhong et al [45] reported that 14 of 946 (1.48%) of the pregnant women in their study were classified as having anxiety at the moment of enrollment (GA<16 weeks). In late pregnancy (GA≥28 weeks), Yu et al [46] stated that the prevalence of the classification of anxiety was 7.9%. Both those studies showed a lower prevalence of the classification of anxiety than the prevalence of the classification of anxiety in our study (10/75, 13.33%) at the moment of enrollment and 34.67% (26/75) at 32 weeks of GA.

PHQ-9

At 16 weeks of GA, 13.71% (159/1160) of the study population in the study of Avalos et al [47] were diagnosed as clinically depressed, which is almost 5% more than observed in our study at the moment of enrollment (7/75, 9.33%). In later pregnancy, the study of Gallis et al [48] reported a higher prevalence of women diagnosed as clinically depressed in their third trimester compared to our study population (570/1154, 49.39% vs 22/75, 29.33%, respectively). This is a comparison to the study of Yu et al [46], where the prevalence of depressive symptoms in late pregnancy (GA≥28 weeks) was 20% lower compared to the pregnant women in our study at 32 weeks of GA (75/813, 9.2%; 95% CI 7.2%-77.2% vs 22/75, 29.33%). Finally, participants who were in their third trimester in the study of Gallis et al [48] had a mean PHQ-9 score of 6.8 (range 0-27), which is more or less the same as the median PHQ-9 score of our study population (6, range 4-10).

PCS

At both 14 weeks of GA and at 32 weeks of GA, 33.3% (25/75) of participants reported catastrophizing; 4% (3/75) of this catastrophizing was found clinically depressed at enrollment, compared to 5.33% (4/75) at 32 weeks of GA. These numbers are higher than the 27.75% (72/242) of women who catastrophize at 19-21 weeks of GA and the 30.16% (73/242) of catastrophizing women at 34-37 weeks of GA reported by Olsson et al [41].

Strengths and Limitations

Our study is the first to show a significant change in psychological factors during pregnancies at risk for PIH. These results indicate a need for additional psychological support during pregnancies with this kind of complication.

Although the results of this study are promising, there are a number of limitations that should be considered. First, the generalizability of the results may be limited by the single-center design of the study. Second, the study results relied on self-reported data only. To complement the questionnaire data, clinical diagnostic interviews are required. Aside from circumventing shared method variance, this could have the additional advantage of offering the possibility to determine whether the study participants think the symptoms are pregnancy-related [48,49], as several symptoms of depression, that is, fatigue, appetite change, and sleep problems, have been shown to be associated with pregnancy. Third, the questionnaire data were gathered on a single-moment basis. It is possible that exceptional events influenced the respondents' answers to the questionnaires. Third, there was a substantial number loss to follow-up (35/110, 20.53%). There is no information about the reason for loss to follow-up, which could have been of valuable information.

Recommendations for Further Research

It is known that depression rates tend to increase with each trimester, and the risk of generalized anxiety disorder and pain interference significantly increases over time during the third trimester [37,42,50]. In this study, 34.67% (26/75) of women based on the GAD-7 and 29.33% (22/75) of women based on the PHQ-9 had clinical depression. Future research needs to investigate how health care workers can help these women lower their depression rates. Second, pregnancy-specific anxiety is sometimes related to previous negative pregnancy experiences [51]. Additional research needs to be conducted to inform clinical decisions on whether specific mental programs are required for women with a history of PIH pregnancy. Next, this study shows an increase in anxiety and depression scores at 32 weeks of GA compared to the moment of enrollment in the PREMOM program and a decrease in catastrophizing, PCS scale. Data about this evolution in low-risk pregnancies are rare. It would be interesting to explore if the GAD-7, PHQ-9, and PCS scores of these pregnant women with PIH at the moment of enrollment and at 32 weeks of GA are significantly lower or higher compared to those of women with a no- or low-risk pregnancy. Finally, studies have already shown that participants with a high level of catastrophizing could benefit from cognitive behavioral therapy [51]. There are already existing behavioral therapies for non-pregnant women. Modifying those programs for pregnant women, and more specifically for pregnant women at risk for PIH, would have added value to the prenatal care program for them.

Conclusions

The peripartum period has long been known to be associated with increased levels of stress and anxiety, which can be exacerbated by PIH. This study shows that pregnant women at risk for PIH have higher scores on the GAD-7 and PHQ-9 at 32 weeks of GA, compared to the moment of enrollment. The subscale scores of the PCS were all lower at 32 weeks of GA compared with 14 weeks of GA. Further research is recommended to explore if the GAD-7, PHQ-9, and PCS scores of these pregnant women with PIH at the moment of enrollment and at 32 weeks of GA are significantly lower or higher

compared to women with a no- or low-risk pregnancy. The knowledge that follows from this research can help implement strategies to manage pregnant women at risk for PIH with their feelings of stress and anxiety.

Acknowledgments

This research is part of the Limburg Clinical Research Center Uhassele, Ziekenhuis Oost-Limburg, Jessa, supported by the foundation Limburg Sterk Merk, province of Limburg, Flemish government, Hasselt University, Jessa Hospital, and Ziekenhuis Oost-Limburg. This research was also part of TRACE, a joint venture between Ziekenhuis Oost-Limburg and Faculty of Psychology and Educational Sciences of KU Leuven.

Conflicts of Interest

None declared.

References

1. Slade A, Cohen LJ, Sadler LS, Miller M. The psychology and psychopathology of pregnancy: reorganization and transformation. In: Zeanah CH, editor. *Handbook of Infant Mental Health, Third Edition*. New York, NY: Guilford Press; 2012:22-39
2. Williams KE, Koleva H. Identification and treatment of peripartum anxiety disorders. *Obstet Gynecol Clin North Am* 2018;45(3):469-481 [FREE Full text] [doi: [10.1016/j.ogc.2018.04.001](https://doi.org/10.1016/j.ogc.2018.04.001)] [Medline: [30092922](https://pubmed.ncbi.nlm.nih.gov/30092922/)]
3. Johnson RC, Slade P. Obstetric complications and anxiety during pregnancy: is there a relationship? *J Psychosom Obstet Gynaecol* 2003;24(1):1-14 [doi: [10.3109/01674820309042796](https://doi.org/10.3109/01674820309042796)] [Medline: [12685335](https://pubmed.ncbi.nlm.nih.gov/12685335/)]
4. Matthey S. Using the Edinburgh postnatal depression scale to screen for anxiety disorders. *Depress Anxiety* 2008;25(11):926-931 [doi: [10.1002/da.20415](https://doi.org/10.1002/da.20415)] [Medline: [18041072](https://pubmed.ncbi.nlm.nih.gov/18041072/)]
5. Milgrom J, Gemmill AW, Bilszta JL, Hayes B, Barnett B, Brooks J, et al. Antenatal risk factors for postnatal depression: a large prospective study. *J Affect Disord* 2008;108(1-2):147-157 [FREE Full text] [doi: [10.1016/j.jad.2007.10.014](https://doi.org/10.1016/j.jad.2007.10.014)] [Medline: [18067974](https://pubmed.ncbi.nlm.nih.gov/18067974/)]
6. Bergman K, Sarkar P, Glover V, O'Connor TG. Maternal prenatal cortisol and infant cognitive development: moderation by infant-mother attachment. *Biol Psychiatry* 2010;67(11):1026-1032 [FREE Full text] [doi: [10.1016/j.biopsych.2010.01.002](https://doi.org/10.1016/j.biopsych.2010.01.002)] [Medline: [20188350](https://pubmed.ncbi.nlm.nih.gov/20188350/)]
7. O'Connor TG, Heron J, Golding J, Beveridge M, Glover V. Maternal antenatal anxiety and children's behavioural/emotional problems at 4 years. Report from the avon longitudinal study of parents and children. *Br J Psychiatry* 2002;180:502-508 [FREE Full text] [doi: [10.1192/bjp.180.6.502](https://doi.org/10.1192/bjp.180.6.502)] [Medline: [12042228](https://pubmed.ncbi.nlm.nih.gov/12042228/)]
8. Stevenson-Hinde J, Shouldice A, Chicot R. Maternal anxiety, behavioral inhibition, and attachment. *Attach Hum Dev* 2011;13(3):199-215 [doi: [10.1080/14616734.2011.562409](https://doi.org/10.1080/14616734.2011.562409)] [Medline: [21506027](https://pubmed.ncbi.nlm.nih.gov/21506027/)]
9. Somerville S, Byrne SL, Dedman K, Hagan R, Coo S, Oxnam E, et al. Detecting the severity of perinatal anxiety with the perinatal anxiety screening scale (PASS). *J Affect Disord* 2015;186:18-25 [FREE Full text] [doi: [10.1016/j.jad.2015.07.012](https://doi.org/10.1016/j.jad.2015.07.012)] [Medline: [26226429](https://pubmed.ncbi.nlm.nih.gov/26226429/)]
10. Black KD. Stress, symptoms, self-monitoring confidence, well-being, and social support in the progression of preeclampsia/gestational hypertension. *J Obstet Gynecol Neonatal Nurs* 2007;36(5):419-429 [doi: [10.1111/j.1552-6909.2007.00173.x](https://doi.org/10.1111/j.1552-6909.2007.00173.x)] [Medline: [17880312](https://pubmed.ncbi.nlm.nih.gov/17880312/)]
11. Leeners B, Stiller R, Neumaier-Wagner P, Kuse S, Schmitt A, Rath W. Psychosocial distress associated with treatment of hypertensive diseases in pregnancy. *Psychosomatics* 2008;49(5):413-419 [FREE Full text] [doi: [10.1176/appi.psy.49.5.413](https://doi.org/10.1176/appi.psy.49.5.413)] [Medline: [18794510](https://pubmed.ncbi.nlm.nih.gov/18794510/)]
12. Gray BA. Hospitalization history and differences in self-rated pregnancy risk. *West J Nurs Res* 2006;28(2):216-229 discussion 230-3 [FREE Full text] [doi: [10.1177/0193945905282305](https://doi.org/10.1177/0193945905282305)] [Medline: [16513920](https://pubmed.ncbi.nlm.nih.gov/16513920/)]
13. Stahl K, Hundley V. Risk and risk assessment in pregnancy - do we scare because we care? *Midwifery* 2003;19(4):298-309 [FREE Full text] [doi: [10.1016/s0266-6138\(03\)00041-x](https://doi.org/10.1016/s0266-6138(03)00041-x)] [Medline: [14623509](https://pubmed.ncbi.nlm.nih.gov/14623509/)]
14. Hatmaker DD, Kemp VH. Perception of threat and subjective well-being in low-risk and high-risk pregnant women. *J Perinat Neonatal Nurs* 1998;12(2):1-10 [doi: [10.1097/00005237-199809000-00002](https://doi.org/10.1097/00005237-199809000-00002)] [Medline: [9782880](https://pubmed.ncbi.nlm.nih.gov/9782880/)]
15. Dagklis T, Papazisis G, Tsakiridis I, Chouliara F, Mamopoulos A, Rousso D. Prevalence of antenatal depression and associated factors among pregnant women hospitalized in a high-risk pregnancy unit in Greece. *Soc Psychiatry Psychiatr Epidemiol* 2016;51(7):1025-1031 [FREE Full text] [doi: [10.1007/s00127-016-1230-7](https://doi.org/10.1007/s00127-016-1230-7)] [Medline: [27138949](https://pubmed.ncbi.nlm.nih.gov/27138949/)]
16. Abrar A, Fairbrother N, Smith AP, Skoll A, Albert AYK. Anxiety among women experiencing medically complicated pregnancy: a systematic review and meta-analysis. *Birth* 2020;47(1):13-20 [FREE Full text] [doi: [10.1111/birt.12443](https://doi.org/10.1111/birt.12443)] [Medline: [31222840](https://pubmed.ncbi.nlm.nih.gov/31222840/)]
17. Barber CC, Starkey NJ. Predictors of anxiety among pregnant New Zealand women hospitalised for complications and a community comparison group. *Midwifery* 2015;31(9):888-896 [FREE Full text] [doi: [10.1016/j.midw.2015.04.017](https://doi.org/10.1016/j.midw.2015.04.017)] [Medline: [25987104](https://pubmed.ncbi.nlm.nih.gov/25987104/)]

18. Bauer A, Knapp M, Parsonage M. Lifetime costs of perinatal anxiety and depression. *J Affect Disord* 2016;192:83-90 [FREE Full text] [doi: [10.1016/j.jad.2015.12.005](https://doi.org/10.1016/j.jad.2015.12.005)] [Medline: [26707352](https://pubmed.ncbi.nlm.nih.gov/26707352/)]
19. Goodman JH, Watson GR, Stubbs B. Anxiety disorders in postpartum women: a systematic review and meta-analysis. *J Affect Disord* 2016;203:292-331 [FREE Full text] [doi: [10.1016/j.jad.2016.05.033](https://doi.org/10.1016/j.jad.2016.05.033)] [Medline: [27317922](https://pubmed.ncbi.nlm.nih.gov/27317922/)]
20. Stainton MC, Lohan M, Fethney J, Woodhart L, Islam S. Women's responses to two models of antepartum high-risk care: day stay and hospital stay. *Women Birth* 2006;19(4):89-95 [FREE Full text] [doi: [10.1016/j.wombi.2006.08.001](https://doi.org/10.1016/j.wombi.2006.08.001)] [Medline: [16965946](https://pubmed.ncbi.nlm.nih.gov/16965946/)]
21. Fairbrother N, Young AH, Zhang A, Janssen P, Antony MM. The prevalence and incidence of perinatal anxiety disorders among women experiencing a medically complicated pregnancy. *Arch Womens Ment Health* 2017;20(2):311-319 [FREE Full text] [doi: [10.1007/s00737-016-0704-7](https://doi.org/10.1007/s00737-016-0704-7)] [Medline: [28032213](https://pubmed.ncbi.nlm.nih.gov/28032213/)]
22. Fairbrother N, Young AH, Janssen P, Antony MM, Tucker E. Depression and anxiety during the perinatal period. *BMC Psychiatry* 2015;15(1):206 [FREE Full text] [doi: [10.1186/s12888-015-0526-6](https://doi.org/10.1186/s12888-015-0526-6)] [Medline: [26303960](https://pubmed.ncbi.nlm.nih.gov/26303960/)]
23. Kintiraki E, Papakatsika S, Kotronis G, Goulis DG, Kotsis V. Pregnancy-Induced hypertension. *Hormones (Athens)* 2015;14(2):211-223 [FREE Full text] [doi: [10.14310/horm.2002.1582](https://doi.org/10.14310/horm.2002.1582)] [Medline: [26158653](https://pubmed.ncbi.nlm.nih.gov/26158653/)]
24. Magro-Malosso ER, Saccone G, Di Tommaso M, Roman A, Berghella V. Exercise during pregnancy and risk of gestational hypertensive disorders: a systematic review and meta-analysis. *Acta Obstet Gynecol Scand* 2017;96(8):921-931 [FREE Full text] [doi: [10.1111/aogs.13151](https://doi.org/10.1111/aogs.13151)] [Medline: [28401531](https://pubmed.ncbi.nlm.nih.gov/28401531/)]
25. Kattah AG, Garovic VD. The management of hypertension in pregnancy. *Adv Chronic Kidney Dis* 2013;20(3):229-239 [FREE Full text] [doi: [10.1053/j.ackd.2013.01.014](https://doi.org/10.1053/j.ackd.2013.01.014)] [Medline: [23928387](https://pubmed.ncbi.nlm.nih.gov/23928387/)]
26. Karsnitz DB, Ward S. Spectrum of anxiety disorders: diagnosis and pharmacologic treatment. *J Midwifery Womens Health* 2011;56(3):266-281 [doi: [10.1111/j.1542-2011.2011.00045.x](https://doi.org/10.1111/j.1542-2011.2011.00045.x)] [Medline: [21535374](https://pubmed.ncbi.nlm.nih.gov/21535374/)]
27. Weisberg RB, Paquette JA. Screening and treatment of anxiety disorders in pregnant and lactating women. *Womens Health Issues* 2002;12(1):32-36 [doi: [10.1016/s1049-3867\(01\)00140-2](https://doi.org/10.1016/s1049-3867(01)00140-2)] [Medline: [11786290](https://pubmed.ncbi.nlm.nih.gov/11786290/)]
28. Sutter-Dallay AL, Giaccone-Marcésche V, Glatigny-Dallay E, Verdoux H. Women with anxiety disorders during pregnancy are at increased risk of intense postnatal depressive symptoms: a prospective survey of the MATQUID cohort. *Eur Psychiatry* 2004;19(8):459-463 [doi: [10.1016/j.eurpsy.2004.09.025](https://doi.org/10.1016/j.eurpsy.2004.09.025)] [Medline: [15589703](https://pubmed.ncbi.nlm.nih.gov/15589703/)]
29. Odibo IN, Wendel PJ, Magann EF. Telemedicine in obstetrics. *Clin Obstet Gynecol* 2013;56(3):422-433 [FREE Full text] [doi: [10.1097/GRF.0b013e318290fef0](https://doi.org/10.1097/GRF.0b013e318290fef0)] [Medline: [23903374](https://pubmed.ncbi.nlm.nih.gov/23903374/)]
30. Cruz J, Brooks D, Marques A. Home telemonitoring in COPD: a systematic review of methodologies and patients' adherence. *Int J Med Inform* 2014;83(4):249-263 [FREE Full text] [doi: [10.1016/j.ijmedinf.2014.01.008](https://doi.org/10.1016/j.ijmedinf.2014.01.008)] [Medline: [24529402](https://pubmed.ncbi.nlm.nih.gov/24529402/)]
31. Vandenberg T, Lanssens D, Storms V, Thijs IM, Bamelis L, Grieten L, et al. Relationship between adherence to remote monitoring and patient characteristics: observational study in women with pregnancy-induced hypertension. *JMIR Mhealth Uhealth* 2019;7(8):e12574 [FREE Full text] [doi: [10.2196/12574](https://doi.org/10.2196/12574)] [Medline: [31464190](https://pubmed.ncbi.nlm.nih.gov/31464190/)]
32. Lanssens D, Thijs IM, Gyselaers W, PREMOM II – consortium. Design of the pregnancy remote monitoring II study (PREMOM II): a multicenter, randomized controlled trial of remote monitoring for gestational hypertensive disorders. *BMC Pregnancy Childbirth* 2020;20(1):626 [FREE Full text] [doi: [10.1186/s12884-020-03291-2](https://doi.org/10.1186/s12884-020-03291-2)] [Medline: [33059633](https://pubmed.ncbi.nlm.nih.gov/33059633/)]
33. Lanssens D, Vandenberg T, Smeets CJ, De Cannière H, Molenberghs G, Van Moerbeke A, et al. Remote monitoring of hypertension diseases in pregnancy: a pilot study. *JMIR Mhealth Uhealth* 2017;5(3):e25 [FREE Full text] [doi: [10.2196/mhealth.6552](https://doi.org/10.2196/mhealth.6552)] [Medline: [28279948](https://pubmed.ncbi.nlm.nih.gov/28279948/)]
34. Lanssens D, Vonck S, Storms V, Thijs IM, Grieten L, Gyselaers W. The impact of a remote monitoring program on the prenatal follow-up of women with gestational hypertensive disorders. *Eur J Obstet Gynecol Reprod Biol* 2018;223:72-78 [FREE Full text] [doi: [10.1016/j.ejogrb.2018.02.015](https://doi.org/10.1016/j.ejogrb.2018.02.015)] [Medline: [29500948](https://pubmed.ncbi.nlm.nih.gov/29500948/)]
35. Lanssens D, Vonck S, Storms V, Thijs IM, Grieten L, Gyselaers W. Corrigendum to "the impact of a remote monitoring program on the prenatal follow-up of women with gestational hypertensive disorders" [eur. j. obstet. gynecol. reprod. biol. 223 (2018) 72-78]. *Eur J Obstet Gynecol Reprod Biol* 2018;231:286-287 [FREE Full text] [doi: [10.1016/j.ejogrb.2018.10.049](https://doi.org/10.1016/j.ejogrb.2018.10.049)] [Medline: [30446338](https://pubmed.ncbi.nlm.nih.gov/30446338/)]
36. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med* 2006;166(10):1092-1097 [FREE Full text] [doi: [10.1001/archinte.166.10.1092](https://doi.org/10.1001/archinte.166.10.1092)] [Medline: [16717171](https://pubmed.ncbi.nlm.nih.gov/16717171/)]
37. Simpson W, Glazer M, Michalski N, Steiner M, Frey BN. Comparative efficacy of the generalized anxiety disorder 7-item scale and the Edinburgh postnatal depression scale as screening tools for generalized anxiety disorder in pregnancy and the postpartum period. *Can J Psychiatry* 2014;59(8):434-440 [FREE Full text] [doi: [10.1177/070674371405900806](https://doi.org/10.1177/070674371405900806)] [Medline: [25161068](https://pubmed.ncbi.nlm.nih.gov/25161068/)]
38. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* 2001;16(9):606-613 [FREE Full text] [doi: [10.1046/j.1525-1497.2001.016009606.x](https://doi.org/10.1046/j.1525-1497.2001.016009606.x)] [Medline: [11556941](https://pubmed.ncbi.nlm.nih.gov/11556941/)]
39. Adewuya AO, Ola BA, Afolabi OO. Validity of the patient health questionnaire (PHQ-9) as a screening tool for depression amongst Nigerian university students. *J Affect Disord* 2006;96(1-2):89-93 [FREE Full text] [doi: [10.1016/j.jad.2006.05.021](https://doi.org/10.1016/j.jad.2006.05.021)] [Medline: [16857265](https://pubmed.ncbi.nlm.nih.gov/16857265/)]
40. Darnall BD, Sturgeon JA, Cook KF, Taub CJ, Roy A, Burns JW, et al. Development and validation of a daily pain catastrophizing scale. *J Pain* 2017;18(9):1139-1149 [FREE Full text] [doi: [10.1016/j.jpain.2017.05.003](https://doi.org/10.1016/j.jpain.2017.05.003)] [Medline: [28528981](https://pubmed.ncbi.nlm.nih.gov/28528981/)]

41. Olsson CB, Grooten WJA, Nilsson-Wikmar L, Harms-Ringdahl K, Lundberg M. Catastrophizing during and after pregnancy: associations with lumbopelvic pain and postpartum physical ability. *Phys Ther* 2012;92(1):49-57 [FREE Full text] [doi: [10.2522/ptj.20100293](https://doi.org/10.2522/ptj.20100293)] [Medline: [22016374](https://pubmed.ncbi.nlm.nih.gov/22016374/)]
42. Biaggi A, Conroy S, Pawlby S, Pariante CM. Identifying the women at risk of antenatal anxiety and depression: a systematic review. *J Affect Disord* 2016;191:62-77 [FREE Full text] [doi: [10.1016/j.jad.2015.11.014](https://doi.org/10.1016/j.jad.2015.11.014)] [Medline: [26650969](https://pubmed.ncbi.nlm.nih.gov/26650969/)]
43. Melville JL, Gavin A, Guo Y, Fan M, Katon WJ. Depressive disorders during pregnancy: prevalence and risk factors in a large urban sample. *Obstet Gynecol* 2010;116(5):1064-1070 [FREE Full text] [doi: [10.1097/AOG.0b013e3181f60b0a](https://doi.org/10.1097/AOG.0b013e3181f60b0a)] [Medline: [20966690](https://pubmed.ncbi.nlm.nih.gov/20966690/)]
44. Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. *Psychosom Med* 2002;64(2):258-266 [FREE Full text] [doi: [10.1097/00006842-200203000-00008](https://doi.org/10.1097/00006842-200203000-00008)] [Medline: [11914441](https://pubmed.ncbi.nlm.nih.gov/11914441/)]
45. Zhong QY, Gelaye B, Zaslavsky AM, Fann JR, Rondon MB, Sánchez SE, et al. Diagnostic validity of the generalized anxiety disorder - 7 (GAD-7) among pregnant women. *PLoS One* 2015;10(4):e0125096 [FREE Full text] [doi: [10.1371/journal.pone.0125096](https://doi.org/10.1371/journal.pone.0125096)] [Medline: [25915929](https://pubmed.ncbi.nlm.nih.gov/25915929/)]
46. Yu Y, Zhu X, Xu H, Hu Z, Zhou W, Zheng B, et al. Prevalence of depression symptoms and its influencing factors among pregnant women in late pregnancy in urban areas of Hengyang City, Hunan Province, China: a cross-sectional study. *BMJ Open* 2020;10(9):e038511 [FREE Full text] [doi: [10.1136/bmjopen-2020-038511](https://doi.org/10.1136/bmjopen-2020-038511)] [Medline: [32873680](https://pubmed.ncbi.nlm.nih.gov/32873680/)]
47. Avalos LA, Caan B, Nance N, Zhu Y, Li DK, Quesenberry C, et al. Prenatal depression and diet quality during pregnancy. *J Acad Nutr Diet* 2020;120(6):972-984 [FREE Full text] [doi: [10.1016/j.jand.2019.12.011](https://doi.org/10.1016/j.jand.2019.12.011)] [Medline: [32063456](https://pubmed.ncbi.nlm.nih.gov/32063456/)]
48. Gallis JA, Maselko J, O'Donnell K, Song K, Saqib K, Turner EL, et al. Criterion-related validity and reliability of the urdu version of the patient health questionnaire in a sample of community-based pregnant women in Pakistan. *PeerJ* 2018;6:e5185 [FREE Full text] [doi: [10.7717/peerj.5185](https://doi.org/10.7717/peerj.5185)] [Medline: [30038858](https://pubmed.ncbi.nlm.nih.gov/30038858/)]
49. Sidebottom AC, Harrison PA, Godecker A, Kim H. Validation of the patient health questionnaire (PHQ)-9 for prenatal depression screening. *Arch Womens Ment Health* 2012;15(5):367-374 [doi: [10.1007/s00737-012-0295-x](https://doi.org/10.1007/s00737-012-0295-x)] [Medline: [22983357](https://pubmed.ncbi.nlm.nih.gov/22983357/)]
50. Schetter CD, Tanner L. Anxiety, depression and stress in pregnancy: implications for mothers, children, research, and practice. *Curr Opin Psychiatry* 2012;25(2):141-148 [FREE Full text] [doi: [10.1097/YCO.0b013e3283503680](https://doi.org/10.1097/YCO.0b013e3283503680)] [Medline: [22262028](https://pubmed.ncbi.nlm.nih.gov/22262028/)]
51. Thorn BE, Pence LB, Ward LC, Kilgo G, Clements KL, Cross TH, et al. A randomized clinical trial of targeted cognitive behavioral treatment to reduce catastrophizing in chronic headache sufferers. *J Pain* 2007;8(12):938-949 [doi: [10.1016/j.jpain.2007.06.010](https://doi.org/10.1016/j.jpain.2007.06.010)] [Medline: [17690017](https://pubmed.ncbi.nlm.nih.gov/17690017/)]

Abbreviations

- BP:** blood pressure
- CG:** control group
- GA:** gestational age
- GAD-7:** Generalized Anxiety Disorder-7 scale
- PCS:** Pain Catastrophizing Scale
- PHQ-9:** Patient Health Questionnaire-9
- PIH:** pregnancy-induced hypertension
- PREMOM:** Pregnancy Remote Monitoring
- RM:** remote monitoring

Edited by K Williams; submitted 13.09.22; peer-reviewed by A Dozier, D McDonnell; comments to author 30.03.23; revised version received 25.05.23; accepted 23.06.23; published 06.09.23

Please cite as:

Lanssens D, Vandenberg T, Storms V, Thijs I, Grieten L, Bamelis L, Gyselaers W, Tang E, Luyten P
Changes in Intrapersonal Factors of Participants in the Pregnancy Remote Monitoring Study Who Are at Risk for Pregnancy-Induced Hypertension: Descriptive Quantitative Study
J Med Internet Res 2023;25:e42686
URL: <https://www.jmir.org/2023/1/e42686>
doi: [10.2196/42686](https://doi.org/10.2196/42686)
PMID: [37672324](https://pubmed.ncbi.nlm.nih.gov/37672324/)

©Dorien Lanssens, Thijs Vandenberg, Valerie Storms, Inge Thijs, Lars Grieten, Lotte Bamelis, Wilfried Gyselaers, Eileen Tang, Patrick Luyten. Originally published in the Journal of Medical Internet Research (<https://www.jmir.org>), 06.09.2023. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on <https://www.jmir.org/>, as well as this copyright and license information must be included.